Novavax Statistics
Total Valuation
Novavax has a market cap or net worth of $1.31 billion. The enterprise value is $889.30 million.
| Market Cap | 1.31B |
| Enterprise Value | 889.30M |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Novavax has 164.95 million shares outstanding. The number of shares has decreased by -3.06% in one year.
| Current Share Class | 164.95M |
| Shares Outstanding | 164.95M |
| Shares Change (YoY) | -3.06% |
| Shares Change (QoQ) | +0.79% |
| Owned by Insiders (%) | 0.83% |
| Owned by Institutions (%) | 59.88% |
| Float | 140.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.17 |
| Forward PS | 6.27 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.33
| Current Ratio | 2.33 |
| Quick Ratio | 2.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.19 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -6.51% |
| Return on Invested Capital (ROIC) | -18.01% |
| Return on Capital Employed (ROCE) | -37.46% |
| Weighted Average Cost of Capital (WACC) | 15.42% |
| Revenue Per Employee | $552,465 |
| Profits Per Employee | -$330,748 |
| Employee Count | 749 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 41.92 |
Taxes
In the past 12 months, Novavax has paid $2.42 million in taxes.
| Income Tax | 2.42M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.02% in the last 52 weeks. The beta is 2.42, so Novavax's price volatility has been higher than the market average.
| Beta (5Y) | 2.42 |
| 52-Week Price Change | -5.02% |
| 50-Day Moving Average | 8.67 |
| 200-Day Moving Average | 8.44 |
| Relative Strength Index (RSI) | 47.02 |
| Average Volume (20 Days) | 3,072,587 |
Short Selling Information
The latest short interest is 43.82 million, so 26.57% of the outstanding shares have been sold short.
| Short Interest | 43.82M |
| Short Previous Month | 45.81M |
| Short % of Shares Out | 26.57% |
| Short % of Float | 31.23% |
| Short Ratio (days to cover) | 10.00 |
Income Statement
In the last 12 months, Novavax had revenue of $413.80 million and -$247.73 million in losses. Loss per share was -$1.52.
| Revenue | 413.80M |
| Gross Profit | -10.58M |
| Operating Income | -119.38M |
| Pretax Income | -245.32M |
| Net Income | -247.73M |
| EBITDA | -216.30M |
| EBIT | -234.12M |
| Loss Per Share | -$1.52 |
Balance Sheet
The company has $719.34 million in cash and $297.32 million in debt, with a net cash position of $422.02 million or $2.56 per share.
| Cash & Cash Equivalents | 719.34M |
| Total Debt | 297.32M |
| Net Cash | 422.02M |
| Net Cash Per Share | $2.56 |
| Equity (Book Value) | -190.71M |
| Book Value Per Share | -1.16 |
| Working Capital | 440.52M |
Cash Flow
In the last 12 months, operating cash flow was -$36.90 million and capital expenditures -$5.30 million, giving a free cash flow of -$42.20 million.
| Operating Cash Flow | -36.90M |
| Capital Expenditures | -5.30M |
| Depreciation & Amortization | 17.83M |
| Net Borrowing | 80.66M |
| Free Cash Flow | -42.20M |
| FCF Per Share | -$0.26 |
Margins
Gross margin is -2.56%, with operating and profit margins of -28.85% and -59.87%.
| Gross Margin | -2.56% |
| Operating Margin | -28.85% |
| Pretax Margin | -59.28% |
| Profit Margin | -59.87% |
| EBITDA Margin | -52.27% |
| EBIT Margin | -56.58% |
| FCF Margin | n/a |
Dividends & Yields
Novavax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.06% |
| Shareholder Yield | 3.06% |
| Earnings Yield | -18.89% |
| FCF Yield | -3.22% |
Analyst Forecast
The average price target for Novavax is $14.00, which is 76.10% higher than the current price. The consensus rating is "Buy".
| Price Target | $14.00 |
| Price Target Difference | 76.10% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | -34.99% |
| EPS Growth Forecast (3Y) | -65.88% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 10, 2019. It was a reverse split with a ratio of 1:20.
| Last Split Date | May 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Novavax has an Altman Z-Score of -5.5 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.5 |
| Piotroski F-Score | 1 |